Oryzon Genomics S.A. (ORYZF)
| Previous Close | 2.2000 |
| Open | 1.4100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.4100 - 1.4100 |
| 52 Week Range | 1.4100 - 2.4500 |
| Volume | |
| Avg. Volume | 9 |
| Market Cap | 135.213M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Jul 11, 2024 - Jul 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML)The combination showed substantial antileukemic activity with deep responses and a manageable safety profile, including in patients with high-risk prognostic factorsIadademstat continues to be studied in 1L unfit AML patients through an investigator-initiated study with Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., June 0
- GlobeNewswire
ORYZON to Provide Corporate Progress Updates at Several Events in June
BIO International Convention 2024European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in June. Oryzon will att
- GlobeNewswire
ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and SpainOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases MADRID, Spain and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announc
